nach oben

Erschienen in:

01.08.2014 | Original Article

Does HistoScanning™ predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate

verfasst von: J. Schiffmann, P. Tennstedt, J. Fischer, Zhe Tian, B. Beyer, K. Boehm, M. Sun, G. Gandaglia, U. Michl, M. Graefen, G. Salomon

Erschienen in: World Journal of Urology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The role of HistoScanning™ (HS) in prostate biopsy is still indeterminate. Existing literature is sparse and controversial. To provide more evidence according to that important clinical topic, we analyzed institutional data from the Martini-Clinic, Prostate Cancer Center, Hamburg.

Methods

Patients who received prostate biopsy and who also received HS were included in the study cohort. A single examiner, blinded to pathological results, re-analyzed all HS data in accordance with sextants of the prostate. Each sextant was considered as an individual case. Corresponding results from biopsy and HS were analyzed. The area under the receiver-operating characteristic curve (AUC) for the prediction of a positive biopsy by HS was calculated. Furthermore, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were assessed according to different HS signal volume cutoffs (>0, >0.2 and >0.5 ml).

Results

Overall, 198 men were identified and 1,188 sextants were analyzed. The AUC to predict positive biopsy results by HS was 0.58. Sensitivity, specificity, PPV and NPV for HS to predict positive biopsy results per sextant, depending on different HS signal volume cutoffs (>0, >0.2 and >0.5 ml) were 84.1, 27.7, 29.5 and 82.9 %, 60.9, 50.6, 28.8 and 79.7 %, and 40.1, 73.3, 33.1 and 78.8 %, respectively.

Conclusions

Positive HS signals do not accurately predict positive prostate biopsy results according to sextant analysis. We cannot recommend a variation of well-established random biopsy patterns or reduction of biopsy cores in accordance with HS signals at the moment.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71. doi:10.1016/j.eururo.2010.10.039 PubMedCrossRef

Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP III, Howe RJ, Lange PH, Lilja H, Loughlin KR, Mohler J, Moul J, Nadler RB, Patterson SG, Presti JC, Stroup AM, Wake R, Wei JT (2010) NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Cancer Netw 8(2):240–262

Schroder FH, van den Bergh RC, Wolters T, van Leeuwen PJ, Bangma CH, van der Kwast TH, Roobol MJ (2010) Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. Eur Urol 57(2):256–266. doi:10.1016/j.eururo.2009.10.031 PubMedCrossRef

Chun FK, Briganti A, Graefen M, Montorsi F, Porter C, Scattoni V, Gallina A, Walz J, Haese A, Steuber T, Erbersdobler A, Schlomm T, Ahyai SA, Currlin E, Valiquette L, Heinzer H, Rigatti P, Huland H, Karakiewicz PI (2007) Development and external validation of an extended 10-core biopsy nomogram. Eur Urol 52(2):436–444. doi:10.1016/j.eururo.2006.08.039 PubMedCrossRef

Benecchi L, Pieri AM, Melissari M, Potenzoni M, Pastizzaro CD (2008) A novel nomogram to predict the probability of prostate cancer on repeat biopsy. J Urol 180(1):146–149. doi:10.1016/j.juro.2008.03.043 PubMedCrossRef

Rochester MA, Pashayan N, Matthews F, Doble A, McLoughlin J (2009) Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population. BMC Urol 9:7. doi:10.1186/1471-2490-9-7 PubMedCentralPubMedCrossRef

Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boeve ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strolin P, van Muilekom E, Schroder FH, Bangma CH, Roobol MJ (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63(4):597–603. doi:10.1016/j.eururo.2012.11.005 PubMedCrossRef

Neill MG, Toi A, Lockwood GA, Evans A, Tammsalu L, Fleshner NE (2008) Systematic lateral prostate biopsy—are the benefits worth the costs? J Urol 179(4):1321–1326. doi:10.1016/j.juro.2007.11.065 PubMedCrossRef

Simmons LA, Autier P, Zat’ura F, Braeckman J, Peltier A, Romic I, Stenzl A, Treurnicht K, Walker T, Nir D, Moore CM, Emberton M (2012) Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(). BJU Int 110(1):28–35. doi:10.1111/j.1464-410X.2011.10734.x PubMedCrossRef

10.

Braeckman J, Autier P, Garbar C, Marichal MP, Soviany C, Nir R, Nir D, Michielsen D, Bleiberg H, Egevad L, Emberton M (2008) Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int 101(3):293–298. doi:10.1111/j.1464-410X.2007.07232.x PubMedCrossRef

11.

Braeckman J, Autier P, Soviany C, Nir R, Nir D, Michielsen D, Treurnicht K, Jarmulowicz M, Bleiberg H, Govindaraju S, Emberton M (2008) The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int 102(11):1560–1565. doi:10.1111/j.1464-410X.2008.07878.x PubMedCrossRef

12.

Salomon G, Spethmann J, Beckmann A, Autier P, Moore C, Durner L, Sandmann M, Haese A, Schlomm T, Michl U, Heinzer H, Graefen M, Steuber T (2013) Accuracy of HistoScanning for the prediction of a negative surgical margin in patients undergoing radical prostatectomy. BJU Int 111(1):60–66. doi:10.1111/j.1464-410X.2012.11396.x PubMedCrossRef

13.

Hamann MF, Hamann C, Schenk E, Al-Najar A, Naumann CM, Junemann KP (2013) Computer-aided (HistoScanning) biopsies versus conventional transrectal ultrasound-guided prostate biopsies: do targeted biopsy schemes improve the cancer detection rate? Urology 81(2):370–375. doi:10.1016/j.urology.2012.08.072 PubMedCrossRef

14.

Nunez-Mora C, Garcia-Mediero JM, Patino P, Orellana C, Garrido A, Rojo A, Rendon D (2013) Utility of Histoscanning prior to prostate biopsy for the diagnosis of prostate adenocarcinoma. Actas Urol Esp. doi:10.1016/j.acuro.2013.01.003 PubMed

15.

Macek P, Barret E, Sanchez-Salas R, Galiano M, Rozet F, Ahallal Y, Gaya JM, Durant M, Mascle L, Giedelman C, Lunelli L, Validire P, Nesvadba M, Cathelineau X (2013) Prostate Histoscanning in clinically localized biopsy proven prostate cancer: an accuracy study. J Endourol. doi:10.1089/end.2013.0419 PubMed

16.

Schiffmann J, Fischer J, Tennstedt P, Beyer B, Bohm K, Michl U, Graefen M, Salomon G (2013) Comparison of prostate cancer volume measured by HistoScanning and final histopathological results. World J Urol. doi:10.1007/s00345-013-1211-3 PubMed

17.

Javed SCE, Beveridge S, Bott S, Eden C, Langley S (2013) Does prostate HistoscanningTM accurately identify prostate cancer, measure tumour volume and assess pathological stage prior to radical prostatectomy? J Clin Urol. doi:10.1177/2051415813489682

18.

Javed S, Chadwick E, Edwards AA, Beveridge S, Laing R, Bott S, Eden C, Langley S (2013) Does HistoScanning play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies. BJU Int. doi:10.1111/bju.12568

19.

D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974PubMedCrossRef

20.

Salomon G, Schiffmann J (2014) Real-time elastography for the detection of prostate cancer. Curr Urol Rep 15(3):392. doi:10.1007/s11934-013-0392-z PubMedCrossRef

21.

Bjurlin MA, Meng X, Le Nobin J, Wysock JS, Lepor H, Rosenkrantz AB, Taneja SS (2014) Optimization of prostate biopsy: the role of MRI targeted biopsy in detection, localization, and risk assessment. J Urol. doi:10.1016/j.juro.2014.03.117

22.

Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L, Taneja SS, Emberton M (2013) Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 63(1):125–140. doi:10.1016/j.eururo.2012.06.004 PubMedCrossRef

Titel: Does HistoScanning™ predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate
verfasst von: J. Schiffmann
P. Tennstedt
J. Fischer
Zhe Tian
B. Beyer
K. Boehm
M. Sun
G. Gandaglia
U. Michl
M. Graefen
G. Salomon
Publikationsdatum: 01.08.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 4/2014
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-014-1330-5

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Does HistoScanning™ predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate